Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

O1385

Sigma-Aldrich

Ozagrel hydrochloride hydrate

≥98% (HPLC), solid

Sinonimo/i:

(E)-3-[4-(Imidazol-1-ylmethyl)phenyl]propenoic acid hydrochloride hydrate, OKY-046

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

5 MG
85,90 €

85,90 €


Per informazioni sulla disponibilità, contatta il Servizio Clienti.

Richiedi un ordine bulk

Scegli un formato

Cambia visualizzazione
5 MG
85,90 €

About This Item

Formula empirica (notazione di Hill):
C13H12N2O2 · HCl · xH2O
Numero CAS:
Peso molecolare:
264.71 (anhydrous basis)
Numero MDL:
Codice UNSPSC:
12352200
ID PubChem:
NACRES:
NA.77

85,90 €


Per informazioni sulla disponibilità, contatta il Servizio Clienti.

Richiedi un ordine bulk

Saggio

≥98% (HPLC)

Stato

solid

Condizioni di stoccaggio

desiccated

Colore

white to off-white

Solubilità

H2O: soluble

Temperatura di conservazione

room temp

Stringa SMILE

O.Cl.OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1

InChI

1S/C13H12N2O2.ClH.H2O/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15;;/h1-8,10H,9H2,(H,16,17);1H;1H2/b6-5+;;
OWIZTYOMGVTSDP-TXOOBNKBSA-N

Applicazioni

Ozagrel hydrochloride hydrate has been used as a thromboxane synthase inhibitor:
  • in high cholesterol-diet rats (HC) to test its effect on arteriolar constriction[1]
  • to pre-treat mice to test its effect on lipopolysaccharide (LPS)-induced behavioral changes[2]
  • to test its effect on arteriolar vasoconstriction in hyperglycemic mice[3]

Azioni biochim/fisiol

Ozagrel is a selective thromboxane A2 synthase (TXA2) inhibitor.
Ozagrel is useful in treating lacunar and thrombotic stroke. It blocks vasoconstriction and platelet aggregation.[4] Ozagrel aids in improving the prostacyclin (PGI2)/ thromboxane A2 (TXA2) in the acute phase of cerebral ischemia.[4] It improves endothelial dysfunction in L-methionine-induced hyperhomocysteinemia (HHcy)-induced vascular cognitive impairment and dementia (VCID).[5]

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Gloves, type N95 (US)


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Min-ho Kim et al.
Microvascular research, 73(2), 150-155 (2006-12-13)
This study addresses the role of venule-derived mediators in the arteriolar constriction that accompanies hypercholesterolemia. Constriction was assessed by measuring the tone of small arterioles closely paired with venules in the mesentery of normal cholesterol rats (NC), high cholesterol rats
Yoshio Suzuki et al.
Neurologia medico-chirurgica, 48(6), 241-247 (2008-06-25)
Sub-analysis of the fasudil post-marketing surveillance study compared the safety and efficacy of fasudil plus ozagrel to fasudil only. A total of 3690 patients received fasudil and 1138 received fasudil plus ozagrel between 1995 and 2000. The occurrence of adverse
Seungjun Lee et al.
Microcirculation (New York, N.Y. : 1994), 15(5), 379-387 (2008-06-25)
Reductions in retinal blood flow are observed early in diabetes. Venules may influence arteriolar constriction and flow; therefore, we hypothesized that diabetes would induce the constriction of arterioles that are in close proximity to venules, with the constriction mediated by
Akihiro Koumura et al.
The Journal of pharmacology and experimental therapeutics, 338(1), 337-344 (2011-04-16)
Rho kinase (ROCK), one of the serine/threonine kinases, is involved in pathologic conditions, and its activation causes neuronal cell death. Fasudil, a selective ROCK inhibitor, has been reported to cause increased cerebral blood flow (CBF) in the ischemic brain and
William S Wright et al.
Experimental eye research, 86(3), 528-536 (2008-02-12)
Retinal blood flow in human diabetics has been reported to follow a biphasic time course in which an initial period of reduced flow and ischemia is often followed by a hyperemic and angiogenic phase in which flow can exceed normal

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.